{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:43:30Z","timestamp":1791996210596,"version":"4.4.0"},"reference-count":243,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006529","name":"Race and Difference Initiative, Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006529","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000868"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000868"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["LM2018133"],"award-info":[{"award-number":["LM2018133"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.trim.2022.101539","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:32:21Z","timestamp":1642419141000},"page":"101539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells"],"prefix":"10.1016","volume":"71","author":[{"given":"Tapuchova","family":"Ivana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pytlik","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simara","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesarova","family":"Lenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutna","family":"Irena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2022.101539_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620891","article-title":"Co-reactivation of cytomegalovirus and epstein-barr virus was associated with poor prognosis after allogeneic stem cell transplantation","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0891-5520(05)70157-4","article-title":"Infections following hematopoietic stem cell transplantation","volume":"15","author":"Leather","year":"2001","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0020","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.bbmt.2014.08.010","article-title":"Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in portugal: a five-year retrospective review","volume":"20","author":"Sousa","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2022.101539_bb0030","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/bmt.2012.221","article-title":"Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients","volume":"48","author":"Hiwarkar","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0035","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0040","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb0050","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V78.5.1373.1373","article-title":"Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease","volume":"78","author":"Reusser","year":"1991","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0055","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.V97.5.1232","article-title":"Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation","volume":"97","author":"Cwynarski","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/vox.12857","article-title":"Identification of the best-suited donor for generating virus-specific T cells","volume":"115","author":"Tasn\u00e1dy","year":"2020","journal-title":"Vox Sang."},{"key":"10.1016\/j.trim.2022.101539_bb0065","series-title":"Hum. Cytomegalovirus","first-page":"63","article-title":"Cytomegalovirus Cell Tropism","author":"Sinzger","year":"2008"},{"key":"10.1016\/j.trim.2022.101539_bb0070","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.trim.2022.101539_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/2279-042X.176554","article-title":"The risk factors for cytomegalovirus reactivation following stem cell transplantation","volume":"5","author":"Valadkhani","year":"2016","journal-title":"J. Res. Pharm. Pract."},{"key":"10.1016\/j.trim.2022.101539_bb0080","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V97.6.1572","article-title":"Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome","volume":"97","author":"Cornelissen","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0085","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell\u2013depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0090","first-page":"206","article-title":"The impact of pretransplant herpesvirus serology on acute and chronic graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation","volume":"22","author":"Bostr\u00f6m","year":"1990","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2022.101539_bb0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/tid.12531","article-title":"Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients","volume":"18","author":"Fisher","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Disease definitions working group of the cytomegalovirus drug development forum, definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy080","article-title":"Cytomegalovirus (CMV) disease despite weekly preemptive CMV strategy for recipients of solid organ and hematopoietic stem cell transplantation","volume":"5","author":"Lodding","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ctr.12686","article-title":"Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis","volume":"30","author":"Beam","year":"2016","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0120","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bmt.1702877","article-title":"Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients","volume":"27","author":"Konoplev","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz003","article-title":"Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients","volume":"6","author":"McBride","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0130","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-3062.2011.00706.x","article-title":"A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group","volume":"14","author":"George","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.trim.2022.101539_bb0145","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.idc.2010.01.008","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"24","author":"Ljungman","year":"2010","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.idc.2013.02.005","article-title":"Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients","volume":"27","author":"Razonable","year":"2013","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0160","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcv.2016.10.003","article-title":"Clinical significance of the single nucleotide polymorphism TLR2 R753Q in heart transplant recipients at risk for cytomegalovirus disease","volume":"84","author":"Schneider","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0165","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/infdis\/jiu557","article-title":"Influence of IFNL3\/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation","volume":"211","author":"Manuel","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2006.00618.x","article-title":"Cytomegalovirus in transplantation \u2013 challenging the status quo","volume":"21","author":"Fishman","year":"2007","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3947\/ic.2017.49.3.161","article-title":"Immunological prediction of cytomegalovirus (CMV) Replication risk in solid organ transplantation recipients: approaches for regulating the targeted Anti-CMV prevention strategies","volume":"49","author":"Han","year":"2017","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12594","article-title":"Cytomegalovirus infection in solid organ transplant recipients","volume":"20","author":"Lumbreras","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.trim.2022.101539_bb0185","doi-asserted-by":"crossref","first-page":"S607","DOI":"10.1093\/ofid\/ofy210.1735","article-title":"2079. The relation between panel reactive antibody assay and cytomegalovirus reactivation in seropositive solid organ transplantation recipients","volume":"5","author":"Kwon","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0190","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1086\/315391","article-title":"Human Herpesvirus\u20146 is associated with cytomegalovirus reactivation in liver transplant recipients","volume":"181","author":"Humar","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0195","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1034\/j.1399-0012.2000.140507.x","article-title":"Co-infection of two \u03b2-herpesviruses (CMV and HHV-7) as an increased risk factor for \u2018CMV disease\u2019 in patients undergoing renal transplantation","volume":"14","author":"Chapenko","year":"2000","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0200","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients \u2013 BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2022.101539_bb0205","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0210","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0215","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0220","first-page":"17","article-title":"QuantiFERON \u00ae -CMV assay for the assessment of cytomegalovirus cell-mediated immunity, Expert Rev","volume":"11","author":"Giulieri","year":"2011","journal-title":"Mol. Diagn."},{"key":"10.1016\/j.trim.2022.101539_bb0225","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/cid\/ciu589","article-title":"Preformed frequencies of cytomegalovirus (CMV)\u2013specific memory T and B cells identify protected cmv-sensitized individuals among seronegative kidney transplant recipients","volume":"59","author":"L\u00facia","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0230","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/cid\/ciw370","article-title":"Are we there yet? Impact of the first international standard for cytomegalovirus dna on the harmonization of results reported on plasma samples","volume":"63","author":"Preiksaitis","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0235","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1128\/JCM.42.5.2168-2172.2004","article-title":"Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry","volume":"42","author":"Chemaly","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.trim.2022.101539_bb0240","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/ajt.12388","article-title":"Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients","volume":"13","author":"Manuel","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18433\/J3RC90","article-title":"Clinical outcomes with antiviral prophylaxis or preemptive therapy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis","volume":"20","author":"Hui","year":"2017","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.trim.2022.101539_bb0250","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13016","article-title":"Comparison of universal prophylaxis and preemptive approach for cytomegalovirus associated outcome measures in renal transplant patients: A meta-analysis of available data","volume":"21","author":"Caskurlu","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0255","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0260","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13666","article-title":"Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies","volume":"33","author":"Girmenia","year":"2019","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0265","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/0003-4819-143-12-200512200-00005","article-title":"Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients","volume":"143","author":"Kalil","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003774.pub4","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.trim.2022.101539_bb0275","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/tid.12417","article-title":"REIPI Network, Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+\/R\u2212 solid organ transplant recipients","volume":"17","author":"San-Juan","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0280","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02009-17","article-title":"Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management","volume":"56","author":"Khanna","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.trim.2022.101539_bb0285","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.trim.2022.101539_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112666","article-title":"Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy","volume":"20","author":"Cho","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trim.2022.101539_bb0295","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","author":"Helou","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.trim.2022.101539_bb0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2478\/ahp-2020-0005","article-title":"Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation","volume":"51","author":"Styczy\u0144ski","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.trim.2022.101539_bb0305","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of Cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0310","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0315","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"CMV viral load and mortality after hematopoietic cell transplantation: a cohort study in the era of preemptive therapy","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trim.2022.101539_bb0320","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.trim.2022.101539_bb0325","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.trim.2022.101539_bb0330","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2217\/fmb.15.82","article-title":"Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management","volume":"10","author":"Hanson","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.trim.2022.101539_bb0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.csbj.2015.01.003","article-title":"Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients","volume":"13","author":"G\u00f6hring","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.trim.2022.101539_bb0340","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and characterization of antiviral drug\u2013resistant cytomegalovirus isolates from solid organ transplant recipients","volume":"186","author":"Lurain","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0345","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/519941","article-title":"Incidence and clinical features of ganciclovir- resistant cytomegalovirus disease in heart transplant recipients","volume":"45","author":"Li","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0350","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.trim.2022.101539_bb0355","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0360","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31821fad25","article-title":"Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients","volume":"92","author":"Myhre","year":"2011","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0365","first-page":"805","article-title":"Incidence of ganciclovir resistance in CMV-positive renal transplant recipients and its association with UL97 gene mutations","volume":"16","author":"Aslani","year":"2017","journal-title":"Iran. J. Pharm. Res. IJPR."},{"key":"10.1016\/j.trim.2022.101539_bb0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.00561-13","article-title":"Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens","volume":"58","author":"Minces","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0375","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0380","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.transproceed.2015.09.070","article-title":"Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation","volume":"48","author":"Ambrose","year":"2016","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2022.101539_bb0385","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/tid.12507","article-title":"Resistant cytomegalovirus in intestinal and multivisceral transplant recipients","volume":"18","author":"Timpone","year":"2016","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"10.1016\/j.trim.2022.101539_bb0390","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkn521","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus","volume":"63","author":"Allice","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0395","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1399-3062.2012.00760.x","article-title":"Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients","volume":"14","author":"Kim","year":"2012","journal-title":"Transpl. Infect. Dis. Off. J. Transplant. Soc."},{"key":"10.1016\/j.trim.2022.101539_bb0400","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0405","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41409-018-0257-7","article-title":"Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data","volume":"54","author":"Vejrazkova","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0410","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOT.0000000000000541","article-title":"Drug-resistant cytomegalovirus: clinical implications of specific mutations","volume":"23","author":"Razonable","year":"2018","journal-title":"Curr. Opin. Organ Transp."},{"key":"10.1016\/j.trim.2022.101539_bb0415","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0420","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.trim.2022.101539_bb0425","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2022.101539_bb0430","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0435","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12879-019-4016-1","article-title":"Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient","volume":"19","author":"Jung","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0440","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz375","article-title":"Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with primary immunodeficiency","volume":"6","author":"Popping","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0445","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0450","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.trim.2022.101539_bb0455","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0460","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0465","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0470","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0475","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QCO.0000000000000459","article-title":"Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation","volume":"31","author":"Razonable","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0480","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/1078155218783245","article-title":"Letermovir associated hepatic transaminitis: A case report","volume":"25","author":"Geswein","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.trim.2022.101539_bb0485","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"key":"10.1016\/j.trim.2022.101539_bb0490","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.001","article-title":"In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation","volume":"11","author":"Frietsch","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0495","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.trim.2022.101539_bb0500","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working party of the european group for blood and marrow transplantation","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-5-17","article-title":"CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects","volume":"5","author":"Slezak","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0510","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)\u2013specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0515","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2022.101539_bb0520","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trim.2022.101539_bb0525","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0530","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bmt.2017.232","article-title":"Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT","volume":"53","author":"Qian","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0540","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0545","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb0555","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.healun.2015.12.031","article-title":"Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation","volume":"35","author":"Pierucci","year":"2016","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0560","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a Single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226436","article-title":"Primary Epstein-Barr virus infection with and without infectious mononucleosis","volume":"14","author":"Rostgaard","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trim.2022.101539_bb0570","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of epstein-barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"key":"10.1016\/j.trim.2022.101539_bb0575","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"182","author":"DeStefano","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2022.101539_bb0580","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1086\/514142","article-title":"Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease","volume":"176","author":"Ma\u00f1ez","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0585","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12094-008-0225-6","article-title":"Could other viruses cause pediatric posttransplant lymphoproliferative disorder?","volume":"10","author":"Vila","year":"2008","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb0590","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1182\/blood-2019-128374","article-title":"Non-destructive post-transplant lymphoproliferative disorder shows distinct clinical features with HHV-6 reactivation in a subset","volume":"134","author":"Yamshon","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0595","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0600","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00506","article-title":"Biological difference between epstein\u2013Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact","volume":"10","author":"Ferla","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb0605","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/01.tp.0000521329.94769.9c","article-title":"Post transplant lymphoproliferative disorders and intestinal transplant in children - single center experience","volume":"101","author":"Ming","year":"2017","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0610","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13313","article-title":"Clinical characteristics and outcomes of PTLD following intestinal transplantation","volume":"32","author":"Wozniak","year":"2018","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0615","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0620","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.trim.2022.101539_bb0625","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/150835","article-title":"Molecular pathogenesis of b-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb0630","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1034\/j.1600-6143.2001.10202.x","article-title":"Management of Epstein\u2013Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation","volume":"1","author":"Green","year":"2001","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0635","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0640","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral therapies for herpesviruses: current agents and new directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.trim.2022.101539_bb0645","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1097\/01.TP.0000058745.02123.6F","article-title":"Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy","volume":"75","author":"Sherritt","year":"2003","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0650","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.trim.2006.10.006","article-title":"Quantitative analysis of EBV-specific CD4\/CD8 T cell numbers, absolute CD4\/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD","volume":"17","author":"Sebelin-Wulf","year":"2007","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb0655","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.trim.2022.101539_bb0660","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients \u2013 BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2022.101539_bb0665","doi-asserted-by":"crossref","unstructured":"S. Prockop, E. Doubrovina, S. Suser, G. Heller, J. Barker, P. Dahi, M.A. Perales, E. Papadopoulos, C. Sauter, H. Castro-Malaspina, F. Boulad, K.J. Curran, S. Giralt, B. Gyurkocza, K.C. Hsu, A. Jakubowski, A.M. Hanash, N.A. Kernan, R. Kobos, G. Koehne, H. Landau, D. Ponce, B. Spitzer, J.W. Young, G. Behr, M. Dunphy, S. Haque, J. Teruya-Feldstein, M. Arcila, C. Moung, S. Hsu, A. Hasan, R.J. O'Reilly, Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation, J. Clin. Invest. 130 (n.d.) 733\u2013747. doi:https:\/\/doi.org\/10.1172\/JCI121127.","DOI":"10.1172\/JCI121127"},{"key":"10.1016\/j.trim.2022.101539_bb0670","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0675","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb0680","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0685","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.hoc.2010.11.012","article-title":"Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and EBV","volume":"25","author":"Shiley","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.trim.2022.101539_bb0690","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.3389\/fmicb.2018.03207","article-title":"\u201cNovel\u201d triggers of herpesvirus reactivation and their potential health relevance","volume":"9","author":"Stoeger","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.trim.2022.101539_bb0695","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJM198107093050202","article-title":"Acyclovir prophylaxis of herpes-simplex-virus infections","volume":"305","author":"Saral","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0700","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ajt.12105","article-title":"Herpes simplex virus in solid organ transplantation","volume":"13","author":"Wilck","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0705","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10428190009065823","article-title":"Reactivation of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation","volume":"39","author":"Maeda","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.trim.2022.101539_bb0710","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2990.2011.01167.x","article-title":"The neurobiology of varicella zoster virus infection","volume":"37","author":"Gilden","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.trim.2022.101539_bb0715","first-page":"ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis, open forum","volume":"7","author":"Marra","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.trim.2022.101539_bb0720","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ Can. Med. Assoc. J. J. Assoc. Medicale Can."},{"key":"10.1016\/j.trim.2022.101539_bb0725","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13622","article-title":"the AST infectious diseases community of practice, varicella zoster virus in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Pergam","year":"2019","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0730","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bjhh.2016.05.015","article-title":"Herpes zoster after autologous hematopoietic stem cell transplantation","volume":"38","author":"dos Santos","year":"2016","journal-title":"Rev. Bras. Hematol. E Hemoter."},{"key":"10.1016\/j.trim.2022.101539_bb0735","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41409-019-0717-8","article-title":"Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation","volume":"55","author":"Mascarenhas","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0740","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.tp.0000230432.39447.8b","article-title":"Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis","volume":"82","author":"Humar","year":"2006","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0745","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2007-03-077644","article-title":"One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation","volume":"110","author":"Erard","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0750","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0020-7292(90)90666-9","article-title":"Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS)","volume":"33","author":"Jacobson","year":"1990","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.trim.2022.101539_bb0755","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/cid\/cis879","article-title":"Persistence and antiviral resistance of varicella zoster virus in hematological patients","volume":"56","author":"van der Beek","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0760","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.transproceed.2004.11.023","article-title":"Successful vaccination against varicella zoster virus prior to kidney transplantation","volume":"37","author":"Geel","year":"2005","journal-title":"Transplant. Proc."},{"issue":"2014","key":"10.1016\/j.trim.2022.101539_bb0765","first-page":"e44","article-title":"IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0770","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/14653249.2012.663486","article-title":"Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients","volume":"14","author":"Blyth","year":"2012","journal-title":"Cytotherapy."},{"key":"10.1016\/j.trim.2022.101539_bb0775","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus\u2013specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy."},{"key":"10.1016\/j.trim.2022.101539_bb0780","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1399-3046.2005.00419.x","article-title":"Specific autologous cytotoxic T lymphocytes for chronic varicella in a liver transplanted child","volume":"10","author":"Melzi","year":"2006","journal-title":"Pediatr. Transplant."},{"issue":"Pt 6","key":"10.1016\/j.trim.2022.101539_bb0785","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1099\/0022-1317-72-6-1401","article-title":"Latent human herpesvirus 6 infection of human monocytes\/macrophages","volume":"72","author":"Kondo","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0790","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/JVI.73.1.754-759.1999","article-title":"Human herpesvirus 6 latently infects early bone marrow progenitors in vivo","volume":"73","author":"Luppi","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0795","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2008.162","article-title":"European Conference on Infections in Leukemia, Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0800","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00705-013-1902-5","article-title":"Classification of HHV-6A and HHV-6B as distinct viruses","volume":"159","author":"Ablashi","year":"2014","journal-title":"Arch. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0805","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jmv.2172","article-title":"Latent infection of human herpesvirus 6 in astrocytoma cell line and alteration of cytokine synthesis","volume":"66","author":"Yoshikawa","year":"2002","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0810","first-page":"384","article-title":"Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes","volume":"11","author":"Ahlqvist","year":"2005","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb0815","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/jcm.31.2.416-418.1993","article-title":"Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants","volume":"31","author":"Dewhurst","year":"1993","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.trim.2022.101539_bb0820","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1086\/320000","article-title":"Human herpesviruses 6 and 7 in solid organ transplant recipients","volume":"32","author":"Snydman","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0825","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1432-2277.2012.01443.x","article-title":"Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review","volume":"25","author":"Lautenschlager","year":"2012","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2022.101539_bb0830","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcv.2009.05.018","article-title":"Association of HHV-6 and HHV-7 reactivation with the development of chronic allograft nephropathy","volume":"46","author":"Chapenko","year":"2009","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0835","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00007890-200202270-00021","article-title":"Clinical impact of human herpesvirus 6 infection after liver transplantation","volume":"73","author":"Humar","year":"2002","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0840","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/00007890-199211000-00022","article-title":"A prospective study of human herpesvirus-6 infection in renal transplantation","volume":"54","author":"Yoshikawa","year":"1992","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0845","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1086\/428060","article-title":"Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation","volume":"40","author":"Zerr","year":"2005","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.trim.2022.101539_bb0850","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.bbmt.2018.04.021","article-title":"Human Herpesvirus-6B reactivation is a risk factor for grades II to IV acute graft-versus-host disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"24","author":"Phan","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0855","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/transplantology2010002","article-title":"Management of herpesvirus infections in hematopoietic cell transplant recipients","volume":"2","author":"Styczynski","year":"2021","journal-title":"Transplantology."},{"key":"10.1016\/j.trim.2022.101539_bb0860","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2012-05-430413","article-title":"Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation","volume":"121","author":"Gerdemann","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0865","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T-cells as treatment for AdV, EBV, CMV, BKV and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0870","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr Virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb0875","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jmv.20511","article-title":"Latent infection of human herpesvirus 7 in CD4+ T lymphocytes","volume":"78","author":"Miyake","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.trim.2022.101539_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3476(94)70113-X","article-title":"Human herpesvirus 7: another causal agent for roseola (exanthem subitum)","volume":"125","author":"Tanaka","year":"1994","journal-title":"J. Pediatr."},{"key":"10.1016\/j.trim.2022.101539_bb0885","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1097\/00007890-200006150-00032","article-title":"Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection: 1","volume":"69","author":"Kidd","year":"2000","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101539_bb0890","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/367677","article-title":"Human herpesvirus (HHV)\u20136 and HHV\u20137: Two closely related viruses with different infection profiles in stem cell transplantation recipients","volume":"187","author":"Boutolleau","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0895","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13518","article-title":"The AST infectious diseases community of practice, human herpesvirus 6, 7, and 8 in solid organ transplantation: Guidelines from the american society of transplantation infectious diseases community of practice","volume":"33","author":"Pellett Madan","year":"2019","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2022.101539_bb0900","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-6143.2008.02501.x","article-title":"An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes","volume":"9","author":"Humar","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0905","series-title":"Hum. Herpesviruses Biol. Ther. Immunoprophyl","article-title":"Introduction to the human \u03b3-herpesviruses","author":"Longnecker","year":"2007"},{"key":"10.1016\/j.trim.2022.101539_bb0910","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2046-4053-3-11","article-title":"HHV-8 seroprevalence: a global view","volume":"3","author":"Rohner","year":"2014","journal-title":"Syst. Rev."},{"key":"10.1016\/j.trim.2022.101539_bb0915","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman\u2019s disease","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb0920","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2022.101539_bb0925","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(95)91619-9","article-title":"Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi\u2019s sarcoma","volume":"346","author":"Whitby","year":"1995","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.trim.2022.101539_bb0930","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1128\/JCM.41.8.3897-3900.2003","article-title":"Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR","volume":"41","author":"Sergerie","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.trim.2022.101539_bb0935","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/588820","article-title":"Valganciclovir for suppression of human herpesvirus 8 replication: a randomized, double-blind, placebo-controlled, crossover trial","volume":"198","author":"Casper","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0940","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1097\/QAD.0b013e3283300a91","article-title":"Cellular immune responses and disease control in acute AIDS-associated Kaposi\u2019s sarcoma","volume":"23","author":"Bihl","year":"2009","journal-title":"AIDS."},{"key":"10.1016\/j.trim.2022.101539_bb0945","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Greenberg, Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science."},{"key":"10.1016\/j.trim.2022.101539_bb0950","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcyt.2020.03.092","article-title":"Outcomes and challenges of manufacturing virus-specific cytotoxic T-lymphocytes using IFN-gamma cytokine capture system","volume":"22","author":"Maryamchik","year":"2020","journal-title":"Cytotherapy."},{"key":"10.1016\/j.trim.2022.101539_bb0955","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","article-title":"Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation","volume":"193","author":"Snyder","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.trim.2022.101539_bb0960","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/j.1600-6143.2008.02279.x","article-title":"PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy","volume":"8","author":"Sester","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0965","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13601","article-title":"CD154-expressing CMV-specific T cells associate with freedom from DNAemia and may be protective in seronegative recipients after liver or intestine transplantation","volume":"24","author":"Ashokkumar","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb0970","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/523652","article-title":"Programmed Death\u20141 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease","volume":"197","author":"Rosa","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0975","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0980","article-title":"Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events","volume":"20","author":"Rogers","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb0985","doi-asserted-by":"crossref","DOI":"10.3791\/3627","article-title":"Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus","author":"Hanley","year":"2012","journal-title":"J. Vis. Exp. JoVE."},{"key":"10.1016\/j.trim.2022.101539_bb0990","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.trim.2022.101539_bb0995","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1000","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000479238","article-title":"Robust production of cytomegalovirus pp65-specific T cells using a fully automated IFN-\u03b3 cytokine capture system","volume":"45","author":"Kim","year":"2018","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.trim.2022.101539_bb1005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.trim.2022.101539_bb1010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation: STREPTAMER-BASED ADOPTIVE T-CELL TRANSFER","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.trim.2022.101539_bb1015","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1498-3","article-title":"Clinical-grade generation of peptide-stimulated CMV\/EBV-specific T cells from G-CSF mobilized stem cell grafts","volume":"16","author":"Gary","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trim.2022.101539_bb1020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with CliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"K\u00e1llay","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.trim.2022.101539_bb1025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nm0602-631","article-title":"Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer","volume":"8","author":"Knabel","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2022.101539_bb1030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jfma.2012.02.020","article-title":"Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells","volume":"112","author":"Wang","year":"2013","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.trim.2022.101539_bb1035","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jcyt.2014.05.023","article-title":"Clinical-scale isolation of \u2018minimally manipulated\u2019 cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease","volume":"16","author":"Odendahl","year":"2014","journal-title":"Cytotherapy."},{"key":"10.1016\/j.trim.2022.101539_bb1040","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.bbmt.2008.07.014","article-title":"Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation","volume":"14","author":"Bao","year":"2008","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcyt.2013.11.010","article-title":"The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care","volume":"16","author":"Saglio","year":"2014","journal-title":"Cytotherapy."},{"key":"10.1016\/j.trim.2022.101539_bb1050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.trim.2022.101539_bb1055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1\u2013specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb1060","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-0296","article-title":"Autologous T-cell Therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma","volume":"74","author":"Schuessler","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trim.2022.101539_bb1065","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1070","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2015-08-664755","article-title":"TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells","volume":"126","author":"Menger","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00733","article-title":"Latent cytomegalovirus (CMV) infection does not detrimentally alter T cell Responses in the healthy old, but increased latent CMV carriage is related to expanded CMV-specific T cells","volume":"8","author":"Jackson","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb1080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12967-020-02301-3","article-title":"High-intensity interval training in allogeneic adoptive T-cell immunotherapy \u2013 a big HIT?","volume":"18","author":"Heinemann","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trim.2022.101539_bb1085","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7131359","article-title":"Exercise as an adjuvant therapy for hematopoietic stem cell mobilization","volume":"2016","author":"Emmons","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.trim.2022.101539_bb1090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep25852","article-title":"A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy","volume":"6","author":"Spielmann","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trim.2022.101539_bb1095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/JES.0b013e3182877deb","article-title":"Exercise and hematopoietic stem and progenitor cells: protection, quantity, and function","volume":"41","author":"De Lisio","year":"2013","journal-title":"Exerc. Sport Sci. Rev."},{"key":"10.1016\/j.trim.2022.101539_bb1100","series-title":"Human Cytomegalovirus Infection and the Immune Response to Exercise","first-page":"19","author":"Simpson","year":"2016"},{"key":"10.1016\/j.trim.2022.101539_bb1105","doi-asserted-by":"crossref","first-page":"R1847","DOI":"10.1152\/ajpregu.1997.272.6.R1847","article-title":"Splenectomy impairs lymphocytosis during maximal exercise","volume":"272","author":"Nielsen","year":"1997","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.trim.2022.101539_bb1110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.17219\/acem\/58802","article-title":"The thymus: a forgotten, but very important organ","volume":"25","author":"Zdrojewicz","year":"2016","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.trim.2022.101539_bb1115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbi.2013.05.003","article-title":"The effects of age and latent cytomegalovirus infection on the redeployment of CD8+ T cell subsets in response to acute exercise in humans","volume":"39","author":"Spielmann","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.trim.2022.101539_bb1120","first-page":"120","article-title":"Adverse effects of virus-specific T-cell therapy: an integrative review","volume":"10","author":"Simmons","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.trim.2022.101539_bb1125","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood-2009-07-234906","article-title":"Allo-HLA reactivity of virus-specific memory T cells is common","volume":"115","author":"Amir","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00330","article-title":"Alloreactivity of virus-specific T cells: possible implication of graft-versus-host disease and graft-versus-leukemia effects","volume":"4","author":"Fuji","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb1135","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","article-title":"Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse","volume":"109","author":"Chen","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2022.101539_bb1145","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1150","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010047","article-title":"Adoptive T cell therapy strategies for viral infections in patients receiving haematopoietic stem cell transplantation","volume":"8","author":"Ottaviano","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.trim.2022.101539_bb1155","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-08-2987","article-title":"Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease","volume":"103","author":"Chen","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1160","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.trim.2022.101539_bb1165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1170","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zhao","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1175","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/414959","article-title":"Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic transplantation after nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin","volume":"2013","author":"Veltri","year":"2013","journal-title":"Bone Marrow Res."},{"key":"10.1016\/j.trim.2022.101539_bb1180","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1600-6143.2004.00524.x","article-title":"Graft versus host disease in intestinal transplantation","volume":"4","author":"Mazariegos","year":"2004","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1185","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1600-6143.2004.00406.x","article-title":"Acute graft versus host disease following liver transplantation: the enemy within","volume":"4","author":"Taylor","year":"2004","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1190","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific t-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2022.101539_bb1195","author":"Krauss"},{"key":"10.1016\/j.trim.2022.101539_bb1200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2019-125166","article-title":"Administration of Third-Party Virus-Specific T-Cells (VST) at the time of initial therapy for infection after haemopoietic stem cell transplant is safe and associated with favourable clinical outcomes (the R3ACT-Quickly trial)","volume":"134","author":"Gottlieb","year":"2019","journal-title":"Blood."},{"issue":"30","key":"10.1016\/j.trim.2022.101539_bb1205","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/CJI.0b013e3180335b7a","article-title":"Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens","volume":"1997","author":"Karlsson","year":"2007","journal-title":"J. Immunother. Hagerstown Md"},{"key":"10.1016\/j.trim.2022.101539_bb1210","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trim.2022.101539_bb1215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2017.02.001","article-title":"Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood","volume":"5","author":"Dave","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:01:38Z","timestamp":1760810498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":243,"alternative-id":["S0966327422000132"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101539","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101539"}}